Long-term outcome of 231 patients with essential thrombocythemia: Prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia

Archives of Internal Medicine

Volumn 165, Issue 22, 2005, Pages 2651-2658

  Chim, Chor Sang ^a   Kwong, Yok Lam ^a   Lie, Albert Kwok Wei ^a   Ma, Siu Kwan ^a   Chan, Chi Chung ^b   Wong, Lap Gate ^c   Kho, Bonnie Chi San ^d   Lee, Harold Kwok ^e   Sim, Joycelyn Pui Yin ^d   Chan, Cheuk Hung ^b   Chan, Joyce Chee Wun ^d   Yeung, Yiu Ming ^c   Law, Martin ^a   Liang, Raymond ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^c TUEN MUN HOSPITAL   (Hong Kong)

^d PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

^e PRINCESS MARGARET HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; MELPHALAN;

AGE DISTRIBUTION; CLINICAL TRIAL; DISEASE ASSOCIATION; HUMAN; MEDICAL LITERATURE; MYELOID LEUKEMIA; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SPLENOMEGALY; SURVIVAL; THROMBOCYTOPENIA; THROMBOSIS;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BETA-THALASSEMIA; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FOLLOW-UP STUDIES; HONG KONG; HUMANS; HYDROXYUREA; LEUKEMIA, MYELOID; MALE; MELPHALAN; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELOABLATIVE AGONISTS; MYELOFIBROSIS; PROGNOSIS; RISK FACTORS; SEX FACTORS; SPLENOMEGALY; SURVIVAL ANALYSIS; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOSIS;

EID: 28944455594     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.165.22.2651     Document Type: Review

References (52)

1. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood. 1981;58:916-919.
2. Spivak JL. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol. 2004;41(suppl 3):1-5.
3. Champion KM, Gilbert JG, Asimakopoulos FA, Hinshelwood S, Green AR. Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes. Br J Haematol. 1997;97:920-926.
4. el-Kassar N, Hetet G, Briere J, Grandchamp B. Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood. 1997;89:128-134.
5. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997;34:29-39.
6. Kessler CM. Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders. Semin Hematol. 2004;41(suppl 3):10-14.
7. Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol. 2000;65:132-139.
8. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: longterm follow-up of a randomized clinical trial. Br J Haematol. 2000;110:577-583.
9. Cervantes F, Alvarez-Larran A, Talarn C, Gomez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol. 2002;118:786-790.
10. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8:556-562.
11. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer. 1990;66:549-556.
12. Tefferi A, Fonseca R, Pereira DL, Hoagland HC. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc. 2001;76:22-28.
13. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 1998;91:616-622.
14. Kwong YL, Chiu EK, Liang RH, Chan V, Chan TK. Essential thrombocythemia with bcr/abl rearrangement. Cancer Genet Cytogenet. 1996;89:74-76.
15. Kwong YL, Liang RH, Chiu EK, et al. Essential thrombocythemia: a retrospective analysis of 39 cases. Am J Hematol. 1995;49:39-42.
16. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255-1265.
17. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17:2954-2970.
18. Bennett JM, Catovsky D, Daniel MT, et al; French-American-British (FAB) Cooperative Group. Proposals for the classification of the acute leukaemias. Br J Haematol. 1976;33:451-458.
19. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
20. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol. 2003;82:148-152.
21. Thiele J, Kvasnicka HM. Prefibrotic chronic idiopathic myelofibrosis: a diagnostic enigma? Acta Haematol. 2004;111:155-159.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. Cox DR. Regression models and life-tables. J R Statist Soc Series B. 1972;34:187-220.
24. Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: longterm treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103:216-221.
25. Chim CS, Liang R, Tam CY, Kwong YL. Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. J Clin Oncol. 2001;19:2033-2040.
26. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia: a statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:215-232.
27. Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocythemia: a retrospective study of 103 patients. Cancer. 1991;67:2926-2930.
28. Wolf BC, Neiman RS. Essential thrombocythemia. In: Neiman S, Orazi A, eds. Disorders of the Spleen. Philadelphia, Pa: WB Saunders Co; 1999:173-174.
29. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332:1132-1136.
30. Landolfi R. Bleeding and thrombosis in myeloproliferative disorders. Curr Opin Hematol. 1998;5:327-331.
31. Georgii A, Buesche G, Kreft A. The histopathology of chronic myeloproliferative diseases. Baillieres Clin Haematol. 1998;11:721-749.
32. Barbui T. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Semin Hematol. 2004;41(suppl 3):15-17.
33. Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol. 1991;85:124-127.
34. Ferster A, Sariban E, Meuleman N; Belgian Registry of Sickle Cell Disease Patients Treated With Hydroxyurea. Malignancies in sickle cell disease patients treated with hydroxyurea. Br J Haematol. 2003;123:368-369.
35. Wilson S. Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea. Ann Intern Med. 2000;133:925-926.
36. de Montalembert M, Davies SC. Is hydroxyurea leukemogenic in children with sickle cell disease? Blood. 2001;98:2878-2879.
37. Hanft VN, Fruchtman SR, Pickens CV, Rosse WF, Howard TA, Ware RE. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood. 2000;95:3589-3593.
38. Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90:3370-3377.
39. Census and Statistics Department, Hong Kong. Hong Kong Annual Digest of Statistics: Special Administrative Region. Hong Kong: Census and Statistics Dept; 2003.
40. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med. 1992;92:69-76.
41. Landaw SA. Acute leukemia in polycythemia vera. Semin Hematol. 1986;23:156-165.
42. Silverstein MN, Brown AL Jr, Linman JW. Idiopathic myeloid metaplasia: its evolution into acute leukemia. Arch Intern Med. 1973;132:709-712.
43. Kimura A, Fujimoto T, Inada T, et al. Blastic transformation in essential thrombocythemia: in vitro differentiation of blast cells into granulocytic, erythroid, and megakaryocytic lineages. Cancer. 1990;65:1538-1544.
44. Emilia G, Sacchi S, Temperani P, Longo R, Vecchi A. Progression of essential thrombocythemia to blastic crisis via idiopathic myelofibrosis. Leuk Lymphoma. 1993;9:423-426.
45. Sedlacek SM, Curtis JL, Weintraub J, Levin J. Essential thrombocythemia and leukemic transformation. Medicine (Baltimore). 1986;65:353-364.
46. Yonemitsu H, Okuda K. Essential thrombocythemia terminating in myelofibrosis and myeloblastic transformation. Jpn J Med. 1985;24:57-61.
47. Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer. 1991;67:2658-2663.
48. Bazzan M, Tamponi G, Schinco P, et al. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol. 1999;78:539-543.
49. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
50. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
51. Baxter EJ, Scott LM, Campbell PJ, et al; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
52. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.